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Future targets in the management of systemic sclerosis
A. Tyndall1, M. Matucci-Cerinic2 and U. Mu¨ller-Ladner3
CTDs—such as SSc and SLE and related rheumatic diseases such as RA—have complex, underlying pathogeneses that include fibrosis,
vascular dysfunction, activation of the immune system and inflammation. Although some current therapies for SSc offer benefits to patients,
there is a clear need to investigate potential therapeutic targets. However, the breadth and diversity of cellular pathways and mediators
implicated in these diseases, coupled with inherent redundancies in these systems, has made pre-clinical investigation difficult. Despite this,
recent advances have been made in elucidating the immunological aspects of CTD, including the roles of B cells, T cells, matrix-remodelling
cells and autoantibodies, enabling novel therapeutic approaches including immunoablation to be investigated. The mechanisms underlying
the fibrosis that characterizes SSc are also becoming clearer; and as the putative events that trigger excessive collagen deposition are
identified, so too are potential junctures at which these aberrant processes may be deactivated. Progress is also being made in understanding
the vasculopathy in SSc, and the potential benefits of antioxidants and endothelin receptor antagonists. There have been some significant
advances in the treatments available to SSc patients; however, this spectrum of diseases remains challenging, and continues in some cases
to be associated with high morbidity, increased mortality and poor prognosis.
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Introduction
The term ‘connective tissue disease’ (CTD) can be applied to
numerous conditions including SSc and SLE. Each of these dis-
eases has a complex pathogenesis, with manifestations that
include fibrosis, inflammation and vascular dysfunction (Fig. 1)
[1]. The inflammatory component of these diseases is character-
ized by an aggressive autoimmune activation that may lead to
scarring of tissue and permanent organ damage. The fibrotic
aspect of these diseases can manifest in the skin, internal organs
and the vasculature, and is a hallmark of CTD. The resultant
damage to the vasculature from these aberrant processes leads
to vascular remodelling and tissue ischaemia.
One CTD with a high case-specific mortality is SSc, which
features all of the characteristic immunological, vascular and
fibrotic dysfunctions and is associated in some cases with poor
prognosis and high morbidity. The majority of SSc patients have a
disease form that can be categorized into one of the two major
subsets, dcSSc or lcSSc, depending on the degree of skin involve-
ment and autoantibody profile [2].
Patients with dcSSc typically experience skin thickening prox-
imal and distal to the elbows and knees, which can include the
face. These patients frequently experience internal organ involve-
ment including pulmonary fibrosis (PF), renal crisis and cardiac
involvement. Whilst lcSSc patients can also experience facial man-
ifestations, they have skin thickening distal to the elbows and
knees, present less frequently with internal organ involvement,
and be more prone to calcinosis, oesophageal dysfunction, scler-
odactyly, telangiectases, pulmonary arterial hypertension (PAH)
and digital ulcers (DUs) [2].
A third, less common subset of SSc patients can be described as
having scleroderma overlap syndromes, also known as MCTD.
These patients may present with features of both SSc subtypes,
sometimes together with features of other autoimmune CTDs. A
fourth subgroup of SSc also exists, in which patients present with
the internal organ manifestations of SSc, but without detectable
skin involvement. This rare and unique disease type is called SSc
sine scleroderma.
In general, SSc treatments are determined by the extent and
severity of disease manifestations, and if there is any internal
organ involvement. At present, there are few efficacious treatment
options for SSc, with most current therapies being targeted
towards symptom relief. Understandably, interest exists in identi-
fying new targets to address this unmet medical need.
Laboratory and animal model research to identify the mechan-
isms underlying CTD has proven difficult; the links between
immunological activation, fibrosis and vascular dysfunction are
incompletely understood. Furthermore, whilst disturbances in
cell–cell communication and intracellular signalling are apparent,
the complexities and redundancies inherent within these networks
make their investigation difficult. Future prototypical targets
include many ligands and receptors, including cytokines, vaso-
active molecules, growth factors and components of metabolic
pathways. This article will discuss the current state of understand-
ing of the immunological, vascular and fibrotic mechanisms
underlying CTD, specifically focusing on SSc, and evaluate poten-
tial therapeutic targets.
The underlying pathological mechanisms in SSc
Immunological disturbances
Autoaggressive immunological activation is a key component of
CTD, yet the mechanisms underlying this activity are incompletely
understood. In SSc, disturbances in B-cell homeostasis and the
inappropriate activation of T cells are postulated to contribute
to the fibrosis, microvascular dysfunction and autoimmunity
that characterize this disease. Elevated serum concentrations of
growth factors, ILs, chemokines and other cytokines have also
been measured in these patients [3]. Populations of expanded
clonal T cells have been detected in the skin and blood of SSc
patients, suggesting that proliferation and clonal expansion has
occurred in situ, in response to an as yet unidentified antigen.
Circulating / T cells have been demonstrated to be involved in
the early stages of SSc, with significant infiltration of the skin and
expression of a cytotoxic, type 1 Th cell (Th1) orientation [4, 5].
It has also been proposed that the pattern of cytokine produc-
tion exhibited by skin-infiltrating T lymphocytes in SSc is oriented
towards a Th2 polarization [6]. Activated T cells produce Th2
cytokines including IL-6, -10 and MCP-1—all speculated to be
inducers of fibrosis. However, this paradigm may not be so
simple, since it has been shown that Th2 cells from the skin of
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patients with early-stage SSc may inhibit fibrosis via production of
TNF- [7]. Production of TNF- overrides the profibrotic IL-4, -6
and -10, and impedes collagen production [7]. Correspondingly,
SSc patients who experience a shift in serum cytokine profile from
a Th2 to a Th1 orientation, also experience improvements in skin
fibrosis [8].
Additionally, disturbances in B-cell homeostasis are understood
to contribute towards the SSc phenotype. Sato et al. [9] documen-
ted a 20% increase in B-cell CD19 expression in SSc patients; an
increase comparable with one that leads to autoaggressive anti-
body (Ab) production in mice. Also, the up-regulated expression
of CD80 and CD86 on the memory B cells of SSc patients suggests
that these cells are chronically activated [10].
The effects of B-cell depletion has been investigated in a murine
SSc model, and was demonstrated to suppress development of
skin fibrosis, autoantibody production and hypergammaglobuli-
naemia in newborn mice [11]. Messenger RNA expression profiles
of Th1 and Th2 cytokines were also less imbalanced in treated
mice. However, this intervention was inefficacious in mice with
existing fibrosis, suggesting that imbalances in B-cell homeostasis
may only be important during disease onset [11].
The development of autoaggressive Abs is a central feature of
CTD, with different autoantibody expression profiles being asso-
ciated with different diseases. In SSc, a high (90%) prevalence of
ANAs has been detected, although autoantibody expression dif-
fers within SSc subtypes. Additionally, a putative pathogenic
autoantibody to PDGF receptor (PDGFR) has been recognized
in SSc patients, and implicated in collagen gene overexpression by
fibroblasts [12]. Together, these observations suggest future inter-
ventions that restore immunological homeostasis to CTD patients,
which might yield quantifiable therapeutic benefits. However,
continued investigation and characterization of the mechanisms
underlying autoimmunity are clearly necessary.
Vascular dysfunction
The mechanisms underlying SSc vasculopathy include activation
of vascular endothelial cells and disordered angiogenesis.
Endothelial activation can be measured indirectly by quantifying
the plasma concentration of von Willebrand factor (vWf), pro-
duced by the vascular endothelium following activation or
damage [13]. Plasma vWf concentrations are increased in SSc
patients, particularly when endothelial damage begins to impair
control of vascular tone [14]. Indeed, plasma vWf propeptide con-
centrations are understood to correlate with early pulmonary
involvement and other biochemical markers of disease activity
[13]. Morphological evidence of endothelial cell activation and
damage in CTD can be obtained by measuring the frequency
and nature of microvascular lesions [15]. Apoptotic endothelial
cells characteristic of SSc have also been detected in the early
inflammatory stages of dcSSc and lcSSc [16].
Angiogenic homeostasis is understood to become destabilized
in SSc patients, leading to ischaemia and vascular remodelling
[17, 18]. Increased serum concentrations of the angiogenic
VEGF are detectable, and are understood to correlate with disease
progression [18–21]. Elevated expression of the angiogenic inhibi-
tor endostatin has also been measured in SSc patients, and is
associated with the presence of giant capillaries in nail-fold capil-
laroscopy [22–24].
The expression of urokinase-type plasminogen activator (uPA)
and the uPA receptor (uPAR) by microvascular endothelial cells
(MVECs) is understood to be important to angiogenic control.
However, the MVECs of patients with SSc exhibit increased
expression of a functionally impaired, truncated uPAR [25].
Additionally, disordered regulation of angiogenic remodelling by
the angiopoietins, and their associated receptor tyrosine kinases,
is also understood to occur in some vascular diseases [26, 27].
Furthermore, the expression of activation markers and hyperpla-
sia of microvascular pericytes have been postulated to be impor-
tant links between chronic microvascular damage and fibrosis.
Fibrotic mechanisms
The fibrosis that affects the skin and internal organs of SSc
patients is underpinned by the transition of fibroblasts from a
quiescent state to one of sustained activation. These activated
myofibroblasts characteristically overproduce type I collagen, col-
lagen-modifying enzymes, and other extracellular matrix (ECM)
components. However, the events that trigger this activation are
unknown. Interestingly, the SSc fibroblast phenotype is compar-
able with fibroblasts that have been exposed to excessive signalling
by TGF-, hinting at a potential underlying mechanism [28, 29].
Additionally, interactions between activated SSc fibroblasts and
the ECM may also contribute to excessive collagen deposition,
since the ECM is understood to regulate the activity of mediators
such as TGF- and fibrillin [30, 31].
Future immunological therapies
Conventional treatments for CTD offer only limited efficacy, leav-
ing patients with few therapeutic options. The need for improved
therapies is particularly acute for patients with severe autoimmune
diseases, and therefore the combination of immunoablation plus
autologous haematopoietic stem cell transplantation (HSCT) has
been piloted in these individuals. Local protocols differ, but this
process essentially combines the mobilization and harvest of per-
ipheral blood stem cells, with their purification, selection and
transplantation into patients following chemotherapy [32]. To
date, over 1000 patients have undergone this technique, with sus-
tained remission achieved in several recipients, including over 150
patients with SSc (Table 1) [32, 33]. The success of this procedure
varies between diseases, as does the risk of treatment-related mor-
tality (TRM). However, with growing experience and technical
refinements, the TRM frequency is declining [32, 34].
The European multicentre, prospective, randomized
Autologous Stem cell Transplantation International Scleroderma
(ASTIS) trial is currently under way. This study will compare
FIG. 1. Hypothesis for the pathogenesis of SSc. Adapted from the Lancet [1] with
permission from Elsevier.
TABLE 1. Clinical outcomes up to 60 months for 57 patients with SSc treated using
immunoablation plus HSCT [32]
Patient status Proportion, %








iii50 A. Tyndall et al.
immunoablation and autologous HSCT vs monthly, intravenous
pulse cyclophosphamide therapy in patients with early dcSSc at
high risk of mortality [35]. The primary end point in the ASTIS
trial is event-free survival, defined as the duration between
randomization and death, or development of end-stage organ fail-
ure [35]. Secondary end points include progression-free survival,
TRM and toxicity. To date, 104 out of a planned 108 patients
have been enrolled, with 54 having received HSCT. There have
been no graft failures or unexpected toxicities, and only two
probable TRMs.
Whilst completion of the ASTIS data set is pending, confidence
in this technique is growing, and a sustained ‘reset’ of an auto-
aggressive immune system appears possible [36]. However, the
associated risks mean that strict inclusion and exclusion criteria
must be implemented to optimize outcomes when evaluating this
technique.
Future cellular and molecular targets
The complex underlying pathologies of CTD provide numerous
prototypical targets for therapeutic intervention, including ET-1,
a key mediator of vascular hypertrophy, proliferation, inflamma-
tion, fibrosis and vasoconstriction. ET-1 exerts its effects via the
ETA and ETB receptor subtypes, and can induce collagen synth-
esis and secretion [37, 38]. Elevated ET-1 expression has been
detected in several organs, during both early and late disease
stages in SSc patients, and can induce expression of an SSc phe-
notype in normal fibroblasts [39, 40]. Clinical data have shown
that the oral, dual ET-1 receptor antagonist, bosentan, has bene-
ficial effects in SSc patients particularly with respect to PAH sec-
ondary to their disease [41] and DUs, a debilitating manifestation
in many SSc patients [42] and results in an overall improvement in
quality of life.
As discussed earlier, TGF- has been implicated in SSc patho-
genesis, and a randomized, placebo-controlled trial to evaluate a
recombinant human anti-TGF- Ab (CAT-192) in patients with
early dcSSc has been undertaken [43]. In this pilot study, CAT-192
showed no evidence of efficacy. In addition, more adverse events
and more serious adverse events were recorded in patients receiv-
ing CAT-192 vs placebo, although these events were not more
frequent in the high-dose treatment group [43]. Therefore, based
on current data, therapies targeting TGF- may offer limited
value.
The tyrosine kinase inhibitor imatinib has been demonstrated
to inhibit fibrosis in several models, and to alter the gene and
protein expression profiles of signalling kinases and immunologi-
cal mediators in mast cells [44, 45]. In a murine model of SLE,
imatinib prolonged survival, delivered significant renal protection
and reduced concentrations of biochemical disease markers [46].
Patients with autoimmune CTD may therefore benefit from the
evaluation of imatinib in a controlled trial [44].
The cytokine B-cell activating factor (BAFF) is also understood
to activate B cells, facilitating their maturation and survival
[47–49]. In comparison with normal controls, increased serum
BAFF concentrations are detectable in CTD patients, and
recent data suggest that serum BAFF concentrations may corre-
late with the extent of disease in SSc and primary SS [50, 51].
Observations in vivo suggest that by reversing autoantibody pro-
duction in a setting of established autoimmunity and ameliorating
B-cell-dependent disease manifestations, BAFF blockade may
offer a novel therapeutic approach, [52].
Additionally, the Toll-like receptors (TLR) are key signalling
components in innate immunity, binding lipopolysaccharide and
oligonucleotides, and exerting disease-specific immunomodula-
tory functions. The TLR-9 signalling pathway has been implicated
in autoimmune disease, and postulated as a prototypical target.
In a murine model of SLE, TLR-9 signalling appeared to confer a
protective effect, with TLR-9-deficient lupus mice having a more
severe disease form. Human studies also document a higher
proportion of TLR-9þ B cells and monocytes in patients with
active SLE [53, 54]. Similar results were seen in peripheral
blood mononuclear cells from SSc patients cultured in vitro with
TLR agonists. SSc patients showed increased expression of a
cluster of IFN-regulated genes, including Siglec-1 (CD169, sialo-
adhesin) [55].
Future targets in the treatment of pulmonary fibrosis
Several organ-specific targets, such as renal, gastrointestinal and
cardiac targets, are important in SSc. Lung involvement is, how-
ever, the leading cause of death in SSc, and PF is estimated to
account for 25% of SSc-related mortality [56]. For SSc patients
with PF, the extent of connective tissue deposition in the lungs is a
determinant of prognosis, making early detection an important
goal. However, a scarcity of symptoms or the presence of non-
specific symptoms makes early detection challenging [57].
Traditional immunosuppression can offer modest efficacy in
the treatment of PF, although this approach plays a relatively
minor role in current management. Long-term cyclophosphamide
treatment can deliver moderate improvements in forced vital
capacity [58, 59], although questions remain about optimal treat-
ment regimens. Therapies that are efficacious in vasculitis, as well
as the immunosuppressants mycophenolate mofetil, prednisone
and AZA, might also be beneficial in SSc patients with PF. In
addition, the future use of selective, targeted therapies for PF may
offer improved efficacy with lower toxicity. For example, imatinib
has been shown to exhibit potent anti-fibrotic effects in vitro and
in vivo, and may therefore reduce collagen gene overexpression in
SSc [12, 45].
The Bosentan Use in Interstitial Lung Disease (BUILD 1) trial
evaluated bosentan for the treatment of idiopathic pulmonary
fibrosis (IPF). In these patients, a trend favouring bosentan in
the combined outcome of time-to-disease-progression or death
was observed, an effect that was pronounced in a pre-identified
subpopulation of patients with surgical lung biopsy-proven IPF
[60]. The BUILD 2 trial evaluated bosentan in patients with inter-
stitial lung disease secondary to SSc, but observed no significant
treatment effects [61]. However, patients in this study were
observed to exhibit relatively stable disease. In addition, the suit-
ability of the 6-min walk test for the assessment of treatment
effects in parenchymal lung disease has subsequently been ques-
tioned [62]. The effects of bosentan in PF related to SSc therefore
require further investigation.
Future PF treatments may otherwise involve simultaneous tar-
geting of multiple pathways; a pleiotropic approach. For example,
the Ifigenia study assessed high doses of the antioxidant N-acetyl-
cysteine (NAC) added to standard therapy of prednisone plus
AZA in patients with IPF [63]. Patients treated with NAC experi-
enced reduced declines in pulmonary function at months 6 and 12
vs placebo [63]. A future evaluation of this treatment regimen in
patients with PF related to SSc may therefore be worthy of con-
sideration. Similarly, pirfenidone has demonstrated activity in
multiple fibrotic conditions, with combined anti-inflammatory,
anti-oxidant and anti-fibrotic effects [64].
Regardless of approach, however, future therapeutic advances
in PF may only offer incremental improvements in efficacy, and
therefore trials for novel agents need to be meticulously planned.
Specifically, an appropriate consideration of inclusion and exclu-
sion criteria, choice of sample sizes, data quality, statistical ana-
lysis and the selection of appropriate and robust end points are
essential.
Conclusion
Whilst the underlying pathogeneses of CTD are complex and
incompletely characterized, dysfunction in signalling networks
and cellular processes, including immunity, vascular function
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and connective tissue deposition, are apparent. Accordingly,
research into future CTD therapies is uncovering a diverse multi-
tude of prototypical targets that includes cytokines, growth fac-
tors, vasoactive mediators and cellular targets. Whilst differing
volumes of evidence support each prototypical target, some
approaches, such as the use of anti-TGF- Abs, have been demon-
strated to be of limited value in one small study designed to test
feasibility and safety. Other compounds and treatments, such as
bosentan, NAC and immunoablation plus HSCT, may offer value
as therapeutic tools in future.
Experience suggests that early identification and aggressive
management of CTD may improve long-term outcomes, and
this will no doubt continue to apply in an era of novel therapeutic
approaches. Questions addressing patient selection, optimal
administration routes and therapeutic combinations will, how-
ever, need to be addressed by meticulously planned, controlled
trials, sufficiently powered to detect incremental advances in
safety and efficacy. In conclusion, the continued evaluation of
prototypical targets combined with more effective management
of CTD patients will place us on course to deliver improved out-
comes in the future.
Rheumatology key messages
 The CTDs have complex, underlying pathogeneses that include
fibrosis, vascular dysfunction, activation of the immune system
and inflammation.
 The continued evaluation of prototypical targets combined with
more effective management of patients will place us on course
to deliver improved outcomes in the future.
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